全球生物製药发酵系统市场：市场规模（按产品、应用、最终用户和地区划分）、未来预测

全球生物製药发酵系统市场规模及预测

2024 年生物製药发酵系统市场规模价值 126.4 亿美元，预计到 2032 年将达到 198.5 亿美元，在 2026-2032 年预测期内的复合年增长率为 5.80%。

人口老化加剧、全球慢性病流行以及人类服务消费的不断增长，正推动人们对生物製药的兴趣。这有望在预计的时间内推动全球生物製药发酵系统市场的扩张。 《全球生物製药发酵系统市场报告》对市场进行了全面的评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球生物製药发酵系统市场

生物製药发酵系统可以定义为在密闭容器或发酵槽中，在受控的通气、搅拌、温度和pH条件下培养微生物的过程。细菌是发酵过程的基础。完全依赖微生物的原料药药物以发酵作为唯一的生产途径。例如，真菌产生的抗生素和次级代谢物可作为抗癌和抗感染剂物，革兰氏阴性细菌产生的脂质A可作为佐剂。这些有机分子可以透过多步骤合成，由其基本单元衍生而来。

然而，有机分子本质上非常复杂，可能包含掌性中心、大型特异性环、独特的共轭双键系统等结构。合成路线不仅需要大量开发，而且耗时且成本高于发酵方法。

全球生物製药发酵系统市场概况

人口老化加剧、全球慢性病氾滥以及人类服务消费的上升，正推动人们对生物製药的兴趣。这很可能在预计的时间内推动全球生物製药发酵系统市场的扩张。多家製药公司正在积极制定富有想像力的天然药物新计划并开展创新工作，以满足人们忽视的有益需求。例如，印度最大的开发和推广公司、全球三大胰岛素生物相似药公司之一Biocon已透过毕赤酵母成熟技术推广了RH-胰岛素（重组人类胰岛素）。这是推动全球生物製药发酵系统市场成长的主要因素。

然而，缺乏对生物製药发酵系统领域的认识和训练有素的专业人员可能会阻碍整体市场的成长。此外，引入更先进的技术来升级生产，实现更大规模的生产单位，并提高产品品质正被视为一个有利可图的机会。

经过验证的市场研究利用原始资讯提炼现有数据，检验数据，并以此编製全面的市场研究报告。本研究报告包含对客户感兴趣的市场要素的定量和定性评估。全球生物製药发酵系统市场主要分为几个细分市场，可以提供有关市场最新趋势的分类资料。

目录

第 1 章全球生物製药发酵系统市场简介

• 市场概览
• 分析范围
• 先决条件

第二章执行摘要

第三章 已验证的市场研究分析方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球生物製药发酵系统市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会

第五章全球生物製药发酵系统市场（依产品）

• 概述
• 上游工程产品
  • 生物反应器/发酵罐
  • 生物过程分析仪器
  • 过程监控系统
  • 其他的
• 下游加工产品
  • 过滤/分离
  • 层析法
  • 耗材及配件
  • 其他的

6. 全球生物製药发酵系统市场（依应用）

• 概述
• 抗生素
• 重组蛋白
• 益生菌
• 其他的

7. 全球生物製药发酵系统市场（依最终用户）

• 概述
• 生物製药公司
• CRO（委外研发机构）
• 学术研究所
• 食品工业
• 其他的

8. 全球生物製药发酵系统市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他地区 (ROW)
  • 中东和非洲
  • 拉丁美洲

第九章全球生物製药发酵系统市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章 公司简介

• GE Healthcare
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Sartorius Stedim Biotech
• Merck KGaA
• Eppendorf AG
• F. Hoffmann-La Roche Ltd.
• Nova Biomedicals
• Lonza
• Becton, Dickinson and Company

第十一章 附录

• 相关分析

Biopharmaceutical Fermentation Systems Market Size And Forecast

Biopharmaceutical Fermentation Systems Market size was valued at USD 12.64 Billion in 2024 and is projected to reach USD 19.85 Billion by 2032, growing at a CAGR of 5.80 % during the forecast period 2026-2032.

Increment within the aged population, surge within the pervasiveness of chronic illnesses over the globe and increase in human services consumption drive interest for biopharmaceuticals. This is most likely to aim to fuel the expansion of the global Biopharmaceutical Fermentation Systems Market during the estimated period. The Global Biopharmaceutical Fermentation Systems Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Biopharmaceutical Fermentation Systems Market Definition

Biopharmaceutical fermentation systems can be defined as the process of incubating microorganisms within an enclosed tank or a fermenter, under controlled conditions of aeration, agitation, temperature, and pH. Bacteria are used as the basis of fermentation processes. Chemical APIs that rely solely on microorganisms have fermentation as the only route to produce it. Some of the examples are, antibiotics or secondary metabolites made in fungi serving as anticancer or anti-infectious agents, or lipid A made in gram-negative bacteria serving as adjuvants. Through multi-steps synthesis, such organic molecules can be derived from their building blocks.

However, organic molecules are quite complex in nature, potentially encompassing structures such as chiral centers, large stereospecific rings, or unique conjugated double bond systems. Going down the synthetic route not only requires significant development but is time-consuming and involves higher costs than the fermentation option.

Global Biopharmaceutical Fermentation Systems Market Overview

Increment within the aged population, surge within the pervasiveness of chronic illnesses over the globe, and increase in human services consumption drive interest for biopharmaceuticals. This is most likely to aiming to fuel the expansion of the global Biopharmaceutical Fermentation Systems Market during the estimated period. A few pharmaceutical organizations are occupied with innovative work of imaginative new plans and natural medications to satisfy the neglected helpful needs. For instance, Biocon, India's biggest, development drove, completely incorporated biopharmaceutical organization which positions among top three biosimilar worldwide players for insulin, has popularized the RH-insulin (recombinant human insulin) through Pichia maturation innovation. This is the major factor that boosts the growth of the global Biopharmaceutical Fermentation Systems Market.

However, lack of awareness and trained professionals in the field for biopharmaceutical fermentation systems might hamper the overall growth of the market. Moreover, introducing more advanced technologies to upgrade production, allow massive production units, and improve product quality approaches as profitable opportunities.

Verified Market Research narrows down the available data using primary sources to validate the data and use it in compiling a full-fledged market research study. The report contains a quantitative and qualitative estimation of market elements which interests the client. The "Global Biopharmaceutical Fermentation Systems Market" is mainly bifurcated into sub-segments which can provide a classified data regarding latest trends in the market.

Global Biopharmaceutical Fermentation Systems Market: Segmentation Analysis

The Global Biopharmaceutical Fermentation Systems Market is Segmented on the basis of Product, Applications, End User, And Geography.

Biopharmaceutical Fermentation Systems Market, By Product

• Upstream Products
• Bioreactors/Fermenters
• Bioprocess Analyzers
• Process Monitoring Systems
• Others
• Downstream Products
• Filtration & Separation
• Chromatography
• Consumables & Accessories
• Others
• On the basis of product, the market is divided into 2 categories. The Upstream Process Product further studied across Bioreactors/Fermenters, Bioprocess Analyzers, Process Monitoring Systems and others. The Downstream Process Product further studied across Filtration and Separation Instruments, Chromatography Systems, Consumables and Accessories.

Biopharmaceutical Fermentation Systems Market, By Applications

• Antibiotics
• Recombinant Proteins
• Probiotics
• Others
• On the basis of application, Biopharmaceutical Fermentation Systems market is divided into categories as mentioned above. Out of these, the recombinant proteins segment holds a major market share. High reliance on microbial systems for recombinant protein production contributed toward the leading share of the segment

Biopharmaceutical Fermentation Systems Market, By End User

• Biopharmaceutical Companies
• Contract Research Organizations
• Academic Research Institutes
• Food Industry
• Others

Based on End User, the Biopharmaceutical Fermentation System Market studied across Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes, Food Industry and others.

Biopharmaceutical Fermentation Systems Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Biopharmaceutical Fermentation Systems Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The global biopharmaceutical fermentation systems market is dominated by North America and Europe. This is due to the development of latest pharmaceutical companies and improving healthcare sector in U.S. and U.K. This can be the explanation that these regions are dominating the regional front of worldwide biopharmaceutical fermentation systems market from 2021 to 2028.

Key Players

The "Global Biopharmaceutical Fermentation Systems Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as GE Healthcare, Thermo Fisher Scientific Inc., Danaher Corporation, Sartorius Stedim Biotech, Merck KGaA, Eppendorf AG, F. Hoffmann-La Roche Ltd., Nova Biomedicals, Lonza, Becton, Dickinson and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities

5 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Upstream Products
  • 5.2.1 Bioreactors/Fermenters
  • 5.2.2 Bioprocess Analyzers
  • 5.2.3 Process Monitoring Systems
  • 5.2.4 Others
• 5.3 Downstream Products
  • 5.3.1 Filtration & Separation
  • 5.3.2 Chromatography
  • 5.3.3 Consumables & Accessories
  • 5.3.4 Others

6 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY APPLICATIONS

• 6.1 Overview
• 6.2 Antibiotics
• 6.3 Recombinant Proteins
• 6.4 Probiotics
• 6.5 Others

7 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY END USER

• 7.1 Overview
• 7.2 Biopharmaceutical Companies
• 7.3 Contract Research Organizations
• 7.4 Academic Research Institutes
• 7.5 Food Industry
• 7.6 Others

8 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Middle East & Africa
  • 8.5.2 Latin America

9 GLOBAL BIOPHARMACEUTICAL FERMENTATION SYSTEMS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 GE Healthcare
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Thermo Fisher Scientific Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Danaher Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Sartorius Stedim Biotech
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Merck KGaA
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Eppendorf AG
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 F. Hoffmann-La Roche Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Nova Biomedicals
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Lonza
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Becton, Dickinson and Company
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 APPENDIX

• 11.1 Related Research